Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Hulu is nearing a series order for 'The Handmaid’s Tale' spinoff 'The Testaments' before the hit show's final season ...

Hulu’s The Testaments casts its Daisy, a Canadian teen whose world is upended when she discovers her hidden connection to ...

The Handmaid’s Tale creator Bruce Miller has reportedly been working on the show for “several years” now, and stepped down as ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...

The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...

The Testaments, the sequel series to The Handmaid’s Tale, has cast a major leading role. The upcoming series, based on ...